Blaze Bioscience Inc.
United States
35 articles about Blaze Bioscience Inc.
-
Blaze Bioscience Announces FDA Has Granted Fast Track Designation to BLZ-100 (tozuleristide) for Pediatric Central Nervous System Tumors
4/7/2020
Phase 2/3 pivotal trial ongoing in patients up to 30 years of age undergoing surgery for pediatric central nervous system tumors
-
Blaze Bioscience Announces the Publication of Phase 1 Clinical Trial Results for Tumor Paint: BLZ-100 (tozuleristide) in Adults with Glioma
5/9/2019
Positive Phase 1 results in adult glioma patients supported pediatric brain cancer clinical program—now in pivotal studies
-
CORRECTING and REPLACING Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System
11/28/2018
Multi-site clinical study brings together the best in class tumor-targeting imaging agent for brain cancer and the highest sensitivity NIR microscope-based detection device in late stage development
-
Blaze Bioscience Announces the Initiation of Pivotal Clinical Trial for Tumor Paint: BLZ-100 (tozuleristide) and the Canvas Imaging System
11/28/2018
Multi-site clinical study brings together the best in class tumor-targeting imaging agent for brain cancer and the highest sensitivity NIR microscope-based detection device in late stage development
-
Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology. Here’s a look at just a few of these stories.
-
Blaze Bioscience Scores $16 Million to Expand Clinical Trials
10/12/2017
-
Blaze Bioscience Announces Presentation Of Tumor Paint BLZ-100 Clinical Data At Pediatric Neuro-Oncology Basic And Translational Research Conference
6/15/2017
-
Blaze Bioscience Announces Presentation Of Tumor Paint BLZ-100 Clinical Data At American Society of Breast Surgeons (ASBrS) Annual Meeting
4/27/2017
-
Blaze Bioscience Announces Tumor Paint BLZ-100 Publication In International Journal Of Toxicology
3/28/2017
-
Juno and Blaze Bioscience's Success Inspires Fred Hutchinson Cancer Research Center to Spin Out More Companies Faster
6/7/2016
-
ASCO2016: Blaze Bioscience Inc. Announces Trial In Progress Presentation At ASCO 2016 Annual Meeting
5/31/2016
-
Blaze Bioscience Inc. Announces Tumor Paint BLZ-100 Publication In JAMA Otolaryngology Head & Neck Surgery
2/25/2016
-
Blaze Bioscience Inc. To Present Tumor Paint BLZ-100 At SPIE Photonics West Conference
2/11/2016
-
Blaze Bioscience Inc. To Present Tumor Paint Clinical Data At 20th Annual Society For Neuro-Oncology (SNO) Meeting
11/10/2015
-
Morphotek Inc. Announces A License Agreement With Blaze Bioscience Inc. For The Development Of Novel Oncology Imaging Technology
11/9/2015
-
Blaze Bioscience Inc. Announces Presentation At GAC-SC 2015 Conference
10/27/2015
-
Blaze Bioscience Inc. Announces Publication Of Tumor Paint BLZ-100 Data In Cancer Research
10/15/2015
-
Blaze Bioscience Inc. Commences Clinical Trial Of BLZ-100 In Patients With Sarcoma Undergoing Surgery
9/22/2015
-
Blaze Bioscience Inc. Announces Open Enrollment For Phase 1 Clinical Trial Of Tumor Paint BLZ-100 In Patients With Solid Tumor Cancers
7/14/2015
-
Blaze Bioscience Inc.’s BLZ-100 Receives Orphan Drug Designation From FDA For Brain Cancer
7/7/2015